The Direct and Indirect Costs Associated With Overactive Bladder Within a Commercially-Insured Population in the United States

被引：8

作者：

Durden, Emily ^{[1
]}

Walker, David ^{[2
]}

Gray, Stephani ^{[1
]}

Fowler, Robert ^{[1
]}

Juneau, Paul ^{[1
]}

Gooch, Katherine ^{[2
]}

机构：

[1] IBM Co, Truven Hlth Analyt, Bethesda, MD USA

[2] Astellas Pharma Global Dev Inc, Northbrook, IL USA

来源：

JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE | 2018年 / 60卷 / 09期

关键词：

direct costs; economic burden; indirect costs; OAB; overactive bladder; URINARY-TRACT SYMPTOMS; WORK PRODUCTIVITY; INCONTINENCE; CONSEQUENCES; COMORBIDITY; PERFORMANCE; PATTERNS; HEALTH; IMPACT;

D O I：

10.1097/JOM.0000000000001367

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

Objective: To quantify the burden associated with overactive bladder (OAB) within a commercially-insured United States (US) population. Methods: Adults with OAB identified from the MarketScan (R) databases (2008 to 2013) were propensity score matched 1: 1 to non-OAB controls. Perpatient-per-month (PPPM) direct healthcare costs, and indirect costs attributable to workplace absence and short-term disability (STD), were estimated. Results: Adjusted PPPM healthcare costs were higher for OAB patients than matched controls for both direct costs ($3003 vs $1123; P<0.0001) and indirect costs due to STD ($114 vs $98; P<0.05). There was no difference in the indirect costs due to absence between the OAB cases and controls. Conclusions: The direct healthcare costs of OAB patients are substantial. Additional research is needed to quantify the impact of OAB on workplace productivity. Improved management of OAB symptoms may reduce costs and enhance patient quality of life.

引用

页码：847 / 852

页数：6

共 28 条

[1] A Tutorial and Case Study in Propensity Score Analysis: An Application to Estimating the Effect of In-Hospital Smoking Cessation Counseling on Mortality
Austin, Peter C.
[J]. MULTIVARIATE BEHAVIORAL RESEARCH, 2011, 46 (01) : 119 - 151
[2] The performance of different propensity-score methods for estimating differences in proportions (risk differences or absolute risk reductions) in observational studies
Austin, Peter C.
[J]. STATISTICS IN MEDICINE, 2010, 29 (20) : 2137 - 2148
[3] Bonafede MM, 2012, AM J MANAG CARE, V18, P380
[4] Limitations of anticholinergic cycling in patients with overactive bladder (OAB) with urinary incontinence (UI): results from the CONsequences of Treatment Refractory Overactive bLadder (CONTROL) study
Chancellor, Michael B.
Yehoshua, Alon
Waweru, Catherine
Globe, Denise
Cheng, I-Ning
Campbell, Karen L.
Joshi, Manher
Pulicharam, Riya
[J]. INTERNATIONAL UROLOGY AND NEPHROLOGY, 2016, 48 (07) : 1029 - 1036
[5] Long-Term Patterns of Use and Treatment Failure With Anticholinergic Agents for Overactive Bladder
Chancellor, Michael B.
Migliaccio-Walle, Kristen
Bramley, Thomas J.
Chaudhari, Sham L.
Corbell, Catherine
Globe, Denise
[J]. CLINICAL THERAPEUTICS, 2013, 35 (11) : 1744 - 1751
[6] Clemens JQ, 2014, AM J PHARM BENEFIST, V6, P19
[7] The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study
Coyne, Karin S.
Sexton, Chris C.
Irwin, Debra E.
Kopp, Zoe S.
Kelleher, Con J.
Milsom, Ian
[J]. BJU INTERNATIONAL, 2008, 101 (11) : 1388 - 1395
[8] National Community Prevalence of Overactive Bladder in the United States Stratified by Sex and Age
Coyne, Karin S.
Sexton, Chris C.
Vats, Vasudha
Thompson, Christine
Kopp, Zoe S.
Milsom, Ian
[J]. UROLOGY, 2011, 77 (05) : 1081 - 1087
[9] ADAPTING A CLINICAL COMORBIDITY INDEX FOR USE WITH ICD-9-CM ADMINISTRATIVE DATABASES
DEYO, RA
CHERKIN, DC
CIOL, MA
[J]. JOURNAL OF CLINICAL EPIDEMIOLOGY, 1992, 45 (06) : 613 - 619
[10] Economic Costs of Overactive Bladder in the United States
Ganz, Michael L.
Smalarz, Amy M.
Krupski, Tracey L.
Anger, Jennifer T.
Hu, Jim C.
Wittrup-Jensen, Kim U.
Pashos, Chris L.
[J]. UROLOGY, 2010, 75 (03) : 526 - 532

← 1 2 3 →